KFDA to approve Boehringer Ingelheim’s novel, oral anticoagulant

The Korea Food and Drug Administration is likely to approve Pradaxa (dabigatran etexilate), Boehringer Ingelheim’s novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) within this month.

This new treatment will improve the lives of many patients and with preventing stroke, will avoid suffering for a significant proportion of t...